Rob_McCutcheon
@rob_mccutcheon
Psychiatrist & researcher. Interested in networks, neurochemistry, multimodal imaging & psychosis https://scholar.google.co.uk/citations?user=MpA_HXkAAAAJ&hl=en
Come and help us understand how to treat psychotic disorders better. New clinical fellow posts available to study muscarinic agonists as a treatment for early psychosis! my.corehr.com/pls/uoxrecruit…
Once again, @NHSE_WTE have made a decision without consultation and despite strong opposition from students and academics We at @BMAstudents & @BMA_Academics have written to NHSE to demand they restart discussions to return SFP to merit-based recruitment.
We’ve written to @NHSEngland demanding a fairer, better process for future SFP applicants. They promised they would consult students and academics, but haven’t. Today, we’re calling it out. Read our letter below👇and our full statement here: bma.org.uk/news-and-opini…
Published today in Lancet Psychiatry, after 7 years of hard labour... the first long-term head-to-head comparison of two augmentation treatments in treatment resistant depression. Clinical and cost-effectiveness of lithium versus quetiapine augmentat... sciencedirect.com/science/articl…
Clinical research in the UK is under threat, partly because it takes so long to get a study or trial approved. Here are some of my suggested solutions in this BMJ Opinion piece @NIHR @wellcometrust @UKRI_News bmj.com/content/388/bm…
New paper with @Matt_Nour , @tobypill , and Phil Cowen discussing different ways of thinking about and developing psychopharmacological treatments biologicalpsychiatryjournal.com/article/S0006-…
Rolling Thunder - An evening with Professor John Kane | King's College London This will be a pleasure- pioneered use of clozapine, 900 papers, 24 NIH grants, now pro 1st episode services. And (annoyingly)renaissance man. Next Friday @KingsIoPPN kcl.ac.uk/events/rolling…
Can administrative real-world data substitute for RCTs and offer propensity matching to reduce bias? Results often fail to correspond & @LGHemkens et al study showed direction of effect differed in 31% & CI failed to include RCT estimate in 56% pubmed.ncbi.nlm.nih.gov/26858277/
This should be required reading by all graduate students and postdocs | A brief guide to statistical analysis of grouped data in preclinical research nature.com/articles/s4225…
It was great to launch our international guidelines for treatment of schizophrenia at the @SIRSGlobal annual congress - many thanks to all those who contributed, especially @rob_mccutcheon Read here: thelancet.com/journals/lanps… Use the digital tool: psymatik.com
Our letter on why meritocratic selection is the best way to choose doctors for training posts is just out in @TheBJPsych. Lotteries and quotas are bad for both doctors and patients. doi.org/10.1192/bjp.20… Thanks to Ishaac Awatli & @talia_eilon for collaborating!
Privilege to interview John Kane, highlights as folllows media.kcl.ac.uk/media/Rolling+…
Anyone who conducts clinical trials in the UK will be unsurprised by this. Although we have fantastic colleagues in Trust R&D departments and the RDNs, the NHS is so flattened and clinicians so demoralised, that it has become difficult to do more than data-based research.
“Speaking more generally about the operating environment in Britain, Tom Keith-Roach, AstraZeneca’s UK president, told MPs “the UK really is an outlier now as one of the most difficult places in the world” in which to bring new medicines to patients.” thetimes.com/article/0b83e3…
This is correct. It does of course also apply to quite a lot of related research that takes a slightly different editorial slant.
This study should be taken lightly, apart from the biased sample, any benefit experienced when taking SSRIs is likely due to the natural course of one's distress improving over time, other adjustments being made, confounded by the placebo effect & exaggerated by confirmation bias
A fond farewell to @KingsIoPPN @MaudsleyNHS , and giving a lecture Thursday 1600, hybrid eventbrite.co.uk/e/psychosis-st… The Good, the Bad and the Ugly. Will be sticking to the evidence-though hope to be entertaining..
Our new open-access paper “An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders” nature.com/articles/s4422… is on @NatMentHealth
Now recruiting for a clincial fellow at @KingsIoPPN to help lead the first trial of muscarinic agonism in early psychosis, ideal for trainees wanting to get involved in research! my.corehr.com/pls/kclrecruit…
I'm happy to share our Review article in @TrendsCognSci , "Cognitive Maps and Schizophrenia", synthesising evidence for representation-level abnormalities in the condition, and proposing directions for future work. sciencedirect.com/science/articl…
But Guardian (wanting exciting headline at the cost of telling a complete story) fail to make clear that there is *no indication* that any non-anonymised participant data was accessed. *No-one* using UKB data (whether they are doing good science or bad) has access to that.